CEL-SCI Corporation is a biotechnology company that is focused on the development of immunotherapy products for the treatment of cancer and infectious diseases. The company's lead product candidate is Multikine, a therapeutic vaccine that is designed to stimulate the immune system to attack cancer cells. CEL-SCI is also developing products for the treatment of COVID-19 and other infectious diseases. The company was founded in 1983 and is headquartered in Vienna, Virginia.